News

The settlement with the US federal government is for resolving claims that the Danish multinational pharma failed to comply with the US Food and Drug Administration (FDA)-mandated Risk

The collaboration will seek to identify and develop Bicycles to treat rare blood disorders. Bicycles are a new therapeutic modality that combine attributes of antibodies, small molecules and

PATH also announced that several global experts in vaccine development and introduction have joined PATH CVIA to advance these critical vaccine efforts. “We are excited to continue our

Alecensa has significantly decreased  the risk of disease deterioration or death (progression-free survival, PFS) by 85% compared against chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small

Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food

 Glioblastoma multiforme and anaplastic astrocytoma are the most common and most severe forms of non-metastatic brain cancer. According to the Central Brain Tumor Registry of the United States,

Keytruda has been approved as a monotherapy to treat locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy and adults who are not

The Company expects to enter the clinic in Q4 2017, pending the regulatory approval to conduct the clinical trial which is expected shortly. These indolent and rare hormone

The manufacturing license follows an inspection by the Spanish Medicines Agency (AEMPS), and provides production capacity for the potential initial European commercial roll out of Cx601, an investigational